Dear Ms Moniz,
My name is Bob Fiddaman. I am the author of 'The evidence, however, is clear, the Seroxat scandal' and the blog 'Fiddaman Blog'.
A short time ago I was contacted by Ms Joanne Thomas of Pennsylvania. She presented me with an email and attachment that you sent her, namely case number A0348482B.
I have wrote about Joanne's case in two articles, both of which have now had over 6,000 views between them.
I 'd like to ask you a few questions, if I may?
- When your company, in an internal email, suggested that Paxil was the probable cause of Joanne's fetus developing heart defects, why didn't they disseminate this information to Joanne?
- When your company learned that Paxil was the probable cause of Joanne's fetus being born with heart defects, why didn't they inform the FDA?
- When your company learned that Paxil was the probable cause of Joanne's fetus being born with heart defects, why didn't they alter the labelling on the Paxil Information Leaflet?
- Joanne's case against your company was lost on the basis of the Statute of Limitations defence your company lawyers, King & Spalding, they used. However, we both know now that Joanne was well within the limit when she first wrote to your company - what is your company's position on this?
- Why has no apology ever been made to Joanne Thomas?
I'm sure you will run this past your superiors who will, more than likely, run it past King & Spalding. Before you do, I ask you to read the two articles and show some compassion, you are, after all, a woman yourself.
A copy of this email will go public in the near future.
Here are the two articles I wrote. Part II features your email to Joanne.
Ryan, Glaxo's Non-Viable Fetus - Part I
Ryan, Glaxo's Non-Viable Fetus - Part II - The Twists